Original Chlodantane and ADK-918 certificate: environmental resistance and immunostimulation
Patent disclosure · 1996
- What the patent describes
- The accessed Google Patents entry supplies bibliographic identity but no readable experimental description.
- What the source reports
- The abstract claims protection during overheating, hypobaric hypoxia and water deprivation, and improved rat operant activity under fatigue. Filing dates to 13 July 1989; publication was 10 June 1996.
Reported patent results
Experimental results unavailable in the source
Experimental results could not be extracted from the accessed source; the later Chlodantane formulation patent is a separate disclosure.
The accessed Google Patents entry supplies bibliographic identity but no readable experimental description.
Population or model The accessed Google Patents entry supplies bibliographic identity but no readable experimental description.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Original experimental outcomes | Not available in the accessed bibliographic entry | No animal survival percentage or human performance effect is invented |
The original certificate is unavailable. Whether it contains experimental results remains unknown.
Source for these results ↗ · Reviewed 2026-11-06
Patent claims and provenance
Molecule. Historical chloro- and bromo-benzoylaminoadamantane disclosure in the Chlodantane development trail. It must not be conflated with Bromantane solely because bromine is mentioned.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- SU1646256A1 ↗ · 1996-06-10
- Earliest priority / filing
- 1989-07-13 / 1989-07-13
- Original applicant / assignee
- Научно-исследовательский институт фармакологии АМН СССР
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 60531599 · family publications are related filings, not independent studies.
Original title, inventors and related publications
2-(para-bromobenzoyl) or 2-(para-chlorobenzoyl)-aminoadamantanes increasing organism resistance to environment inhabitation extremal factor effect and showing immunostimulating activity
Inventors: И.С. Морозов; Н.Г. Арцимович; Н.В. Климова; Т.А. Фадеева; Н.М. Зайцева; Т.С. Галушина; Н.П. Быков; Б.М. Пятин; Н.И. Авдюнина; О.В. Щербакова; Г.В. Пушкарь; В.В. Каштанова; Т.Г. Хлопушина; Г.А. Кузнецова; И.А. Иванова; А.С. Лосев; Л.П. Ефимова; В.Г. Барчуков; С.А. Сергеева; Т.Д. Карпова; О.В. Агафонова; О.М. Краснова; С.Б. Середенин; Б.А. Бадыштов.
Study limitations and source details
Study limitations
- Only the patent abstract and metadata were recovered; the two experimental tables remain unavailable.
- Abstract toxicity figures lack adequate species/route context here and are not used to rank safety.
Source details
Bibliographic index entry accessed. No readable original experimental description or results tables were available; quantitative extraction requires the original publication.
Bibliographic identity only; experimental results unavailable.
Sources checked
Citation
Author unconfirmed. Original Chlodantane and ADK-918 certificate: environmental resistance and immunostimulation SU1646256A1
Related compounds
Chlodantane
N-(adamantan-2-yl)-4-chlorobenzamide (ADK-910), an experimental small molecule with an adamantane cage joined to a chlorobenzamide. Russian studies examined temperature stress and physical workload.
ADK-918
The para-bromobenzamide counterpart of Chlodantane, N-(adamantan-2-yl)-4-bromobenzamide. It is chemically distinct from Bromantane.
Bromantane
A synthetic adamantane drug, also called Ladasten, studied in Russian fatigue and stress research.